Select year

2024 2023 2022 2021 2020 Earlier

shown/page

15

2024.10.17

Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosesciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

2024.04.30

National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
National Medical Products Administration (NMPA) Approves Chipscreen Biosescience’s Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

2024.03.18

Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis
Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis

2024.03.04

CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer
CAPability-01 study was published in Nature Medicine! Chidamide + sintilimab + bevacizumab explored "no man's land" for the treatment of intestinal cancer

2024.03.18

Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosesciences for inspection and survey
Wang Cheng, Secretary of the Party Committee and Chairman of Sichuan Energy Investment, and his team visited Chipscreen Biosesciences for inspection and survey

Media contact

Media contact

（+86）0755-36993500
pr@cnzywx.com

Z6·尊龙凯时